Subjective Sexual Response to Testosterone Replacement Therapy Based on Initial Serum Levels of Total Testosterone

Reyes-Vallejo, Luis Antonio; Lazarou, Stephen; Morgentaler, Abraham

doi:10.1111/j.1743-6109.2006.00381.x

Cited by 41 publications

(26 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the meantime, clinicians may convert RIA values (expressed in pg/mL) to those consistent with values for EqD or cFT by multiplying by 6.7 (or by 67 if expressed in ng/dl). Clinically useful FT cut-offs in use at our center and elsewhere are 1.5 ng/dL for RIA and the corresponding value of 100 pg/mL for EqD and cFT [20,21].…”

Section: Discussionmentioning

confidence: 99%

Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population

2013

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population

2013

Self Cite

View full text Add to dashboard Cite

show abstract

“…[30] Diğer bir dikkat çekilen nokta ise; testosteron seviyesi düşük-normal seviyede olan kişilerdeki tedaviye yanıtın anlamsız ve tutarsız olduğudur. [31] Bu tutarsızlığın nedeni olarak; düşük-normal total testosteron seviyesi olan kişilerdeki bioaktif testosteronun değişik değerlerde olabileceği düşünülmüştür. [18] Tablo 3.…”

Section: öZetunclassified

The treatment of late-onset hypogonadism

Üçer

Gümüş

2014

Turkish Journal of Urology

View full text Add to dashboard Cite

Late-onset hypogonadism (LOH) in aging men is a clinical and biochemical syndrome caused by an age-related decline in testosterone. Despite published in guidelines and recommendations, uncertainty surrounds the profile of clinical symptoms as well as the biochemical threshold of diagnosis. The only evidence-based treatment of late-onset hypogonadism is testosterone replacement therapy. The actual available evidence of the long-term risks and outcomes of testosterone-replacement therapy remains very limited, and carefully designed placebo-controlled trials of testosterone administration to assess the risks and benefits of such a therapy are required. Until such evidence is available, testosterone treatment should be restricted to elderly men with very low testosterone levels in the presence of clinical symptoms, and the advantages and disadvantages need to be accurately assessed. Careful monitoring of potential side effects is necessary. The purpose of this review is to discuss what is known and what remains unclear with respect to the benefits and risks of testosterone replacement treatment.

show abstract

“…Using T gel, there is a clear relationship between restoring serum T concentrations and improvement in certain parameters of sexual function. Obviously, threshold levels are needed in order to significantly affect improvements in sexual functioning [39,63,[78][79][80].…”

Section: Clinical Studiesmentioning

confidence: 99%

Therapeutic Potential of Testosterone Gels

Lunenfeld

Oettel

2009

Aging Health

View full text Add to dashboard Cite

Aging Health (2009) 5(2), 227-245 of male primary hypogonadism is due to testicular failure, with Klinefelter's syndrome accounting for the majority of cases. Abnormalities at the testicular level result in hypergonadotropic hypogonadism (primary hypogonadism) and at the hypothalamic-pituitary level result in hypogonadotropic hypogonadism (secondary h ypogonadism) (Figure 1).In addition, it has been clearly demonstrated that aging is associated with a decline in both total T and free T levels, with a 20 and 35% incidence of hypogonadism in men aged 60 years and in those over 80 years of age, respectively [2,9]. This decline in T is the result of a combination of a primary steroidogenic defect in the aging Leydig cells [10], decreased pituitary secretory capacity and responsiveness to gonadotropin-releasing hormone [11]. This type of testicular deficiency has been termed late-onset hypogonadism (LOH). Aging is also asso ciated with an increase in sex hormone-binding globulin levels and, consequently, with a slower decline in total T than in free T [12]. The normal diurnal rhythm of T secretion observed in young men is partially lost with aging [13]. Aging is also associated with a decrease in lean body mass, muscle mass and strength, diminished libido, erectile function, decreased bone mass, increased fracture risk and diminished sleep quality -symptoms similar to those observed in hypogonadism, which may need treatment with T. Per definition, male hypogonadism is a clinical syndrome characterized by a reduction in circulating androgens and the presence of signs and symptoms of androgen deficiency. The existence of clinical symptoms is In demographic terms, the global population is estimated to grow from the current 6.5 billion to approximately 9 billion by the year 2050. However, owing to the worldwide prolongation of the mean life expectancy and the drastic reduction of fertility rate, it is projected that the elderly (>60 years) will double during the same period from 688-1964 million [1].Approximately 30% of men aged 60-70 years and 70% of men aged 70-80 years have low bioavailable or free testosterone (T) levels [2]. Symptoms and findings of T deficiency are more or less similar to those associated with aging. They include loss of energy, depressed mood, decreased libido, erectile dysfunction, decreased muscle mass and strength, increased fat mass, frailty, osteopenia and osteoporosis [3]. Clinical trials indicate that T therapy can improve many of these findings [4][5][6][7][8].Testosterone is the principal androgen in men, as well as the prohormone for the biosynthesis of two other sexual steroids: 5α-dihydrotestosterone (DHT) and 17β-estradiol. In human males, T 6-7 mg is secreted by the testes in a circadian rhythm with a nocturnal rise in T followed by a decline during the day. T is necessary for spermatogenesis, penile function, to induce and maintain secondary sexual characteristics, lean muscle mass, bone density and for normal sexual behavior and cognitive function.The administration of T is appropri...

show abstract

Subjective Sexual Response to Testosterone Replacement Therapy Based on Initial Serum Levels of Total Testosterone

Cited by 41 publications

References 16 publications

Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population

Free testosterone by direct and calculated measurement versus equilibrium dialysis in a clinical population

The treatment of late-onset hypogonadism

Therapeutic Potential of Testosterone Gels

Contact Info

Product

Resources

About